Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study.
cervical cancer
cervical intraepithelial neoplasia
cytology
high-risk human papillomavirus testing
mass screening
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
revised:
04
11
2021
received:
31
08
2021
accepted:
29
11
2021
pubmed:
14
12
2021
medline:
29
4
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Several international cervical screening guidelines advise against using high-risk human papillomavirus (HR-HPV) testing in women younger than 30. The rationale for this in young women, lies in the potential for additional detection of both low-grade and high-grade cervical intraepithelial neoplasia (CIN) leading to unnecessary treatments without reducing the burden of cervical cancer. We studied 56 544 women screened at 24 to 29 with HR-HPV testing and 116 858 screened with liquid-based cytology (LBC) in the English HPV screening pilot. They were compared to 528 460 women screened at the age of 30 to 49. We studied the detection of cervical cancer and CIN2/3 across two consecutive screening rounds 3 years apart. At 24 to 29, a positive HR-HPV test detected more cases of cervical cancer in the prevalence round than did a positive LBC test (1.36/1000 screened vs 0.82/1000, OR
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1412-1421Subventions
Organisme : Cancer Research UK
ID : C8162/A25356
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-532.
Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864-871.
Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321-346.
The American College of Obstetricians and Gynecologists. Cervical cancer screening. https://www.acog.org/womens-health/infographics/cervical-cancer-screening. Accessed August 17, 2021.
US Preventive Services Task Force. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320:674-686.
Gov.uk. Cervical screening: programme overview. https://www.gov.uk/guidance/cervical-screening-programme-overview. Accessed August 17, 2021.
Public Health Scotland. Cervical screening. http://www.healthscotland.scot/health-topics/screening/cervical-screening. Accessed August 17, 2021.
Italian Ministry of Health. Screening per il cancro del collo dell'utero. https://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=5543&area=tumori&menu=screening. Accessed August 17, 2021.
Sundhedsstyrelsen. Screening for livmoderhalskraeft; Anbefalinger 2018. https://www.sst.dk/-/media/Udgivelser/2018/Screening-for-livmoderhalskr%C3%A6ft---anbefalinger-maj-2018.ashx?la=da&hash=65F7E23E37E78D27B8D8683722B7C2DE0697A879. Accessed August 17, 2021.
Socialstyrelsen. Screening för livmoderhalscancer: Rekommendation och bedömningsunderlag. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-screeningprogram/2015-6-39.pdf. Accessed March 4, 2020.
von Karsa L, Arbyn A, De Vuyst H, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg: Office for Official Publications of the European Union; 2015.
Melnikow J, Henderson J, Burda B, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:687-705.
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136:178-182.
Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.
Rebolj M, Njor SH, Lynge E. Restriction of human papillomavirus DNA testing to women above age 30. Eur J Cancer Prev. 2012;21:73-81.
Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240.
Rebolj M, Brentnall AR, Mathews C, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer. 2019;121:455-463.
Green LI, Mathews CS, Waller J, Kitchener H, Rebolj M. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing. Int J Cancer. 2021;148:1850-1857.
Richards M Report of the independent review of adult screening programmes in England (Publication reference 01089). https://www.england.nhs.uk/wp-content/uploads/2019/02/report-of-the-independent-review-of-adult-screening-programme-in-england.pdf. Accessed November 24, 2020.
Rimmer J New guidance to help cervical screening providers reduce cytology backlogs. https://phescreening.blog.gov.uk/2017/12/18/new-guidance-to-help-cervical-screening-providers-reduce-cytology-backlogs/. Accessed December 28, 2020.
Henson KE, Elliss-Brookes L, Coupland VH, et al. Data resource profile: National Cancer Registration Dataset in England. Int J Epidemiol. 2020;49:16-16h.
Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer. 2014;110:1841-1846.
Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597.
Department for Communities and Local Government. The English Index of Multiple Deprivation (IMD) 2015-guidance. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/464430/English_Index_of_Multiple_Deprivation_2015_-_Guidance.pdf. Accessed October 30, 2018.
Reed N, Balega J, Barwick T, et al. British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2021;256:433-465.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72-iv83.
Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016;115:1140-1146.
American Cancer Society. Treating cervical cancer. https://www.cancer.org/content/dam/CRC/PDF/Public/8602.00.pdf. Accessed December 14, 2020.
Burger EA, Pedersen K, Sy S, Kristiansen IS, Kim JJ. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway. Br J Cancer. 2017;117:783-790.
Public Health England. Cervical screening: programme and colposcopy management. Guidelines for commissioners, screening providers and programme managers for NHS cervical screening. https://www.gov.uk/government/publications/cervical-screening-programme-and-colposcopy-management. Accessed June 1, 2020.
Macdonald M, Smith J, Tidy J, Palmer JE. Conservative management of CIN2: National Audit of British Society for Colposcopy and Cervical Pathology members' opinion. J Obstet Gynaecol. 2018;38:388-394.
McBride E, Tatar O, Rosberger Z, et al. Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed methods systematic review with meta-analysis. Health Psychol Rev. 2021;15(3):395-429.
van den Akker-van Marie ME, van Ballegooijen M, Rozendaal L, Meijer CJLM, Habbema JDF. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer. 2003;89:1830-1833.
Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJLM, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored National Registry Data. Am J Epidemiol. 2013;178:1161-1169.
Department of Health. Annual HPV vaccine coverage in England in 2010/2011: Routine programme for school year 8 females (12 to 13 years old). https://webarchive.nationalarchives.gov.uk/20130104163933/http://immunisation.dh.gov.uk/annual-hpv-vaccine-coverage-in-england-in-201011-report/. Accessed: December 1, 2020.
Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst. 2016;109:djw216.
Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2018;142:709-718.